Clinical trial
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or…
NCT00480987 · M.D. Anderson Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00480987 |
|---|---|
| Title | Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS) |
| Official title | A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes at First Relapse With Complete Remission Duration < 1 Year |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Sanofi Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia |
| Intervention type | Drug |
| Interventions | Oxaliplatin, Fludarabine, Cytarabine |
| Enrollment | 27 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | Jun 1, 2007 |
| Last update posted | Aug 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: